Cardiovascular complications from COVID-19 increased from 7 percent in March 2020 to nearly 10 percent in December 2021
ACC: COVID-19 Vaccination Cuts Risk for Cardiac Events With SARS-CoV-2 Infection
Findings significant for both partial and complete COVID-19 vaccination
Incident CVD, Mortality Risk Heightened for at Least One Year After COVID-19
Short- and long-term risks found in large study of patients with COVID-19 versus matched contemporary and historical cohorts
Many COVID-19 Hospital Survivors Face Adverse Effects at Six Months
Cardiopulmonary symptoms, financial and functional problems seen six months after COVID-19-related discharge
AHA Presents Up-To-Date Statistics for Cardiovascular Disease
19.05 million deaths estimated for CVD globally in 2020, representing an increase of 18.71 percent from 2010
Free Spike Antigen ID’d in Post-SARS-CoV-2 mRNA Vaccine Myocarditis
However, mRNA vaccine-induced immune responses did not differ for those who developed myocarditis and those who did not
Risk for COVID-19-Linked Endocarditis Up in Patients With Opioid, Cocaine Use Disorders
180-day hospitalization risk significantly increased following endocarditis for those with opioid use disorder, cocaine use disorder
Postop CV Morbidity Down With Increased Time From COVID-19 to Surgery
Odds of major postoperative cardiovascular morbidity reduced with increased time from COVID-19 diagnosis to surgery
Myocarditis Up After Second Dose of mRNA-1273 Versus BNT162b2
Rate of myocarditis higher after receipt of mRNA-1273, particularly for younger men (younger than 40 years)